IMV is evaluating DPX-based assets in several clinical trials in difficult-to-treat cancer indications, including diffuse large B-cell lymphoma (DLBCL), ovarian, breast, and bladder cancer. Previous studies have shown encouraging results, notably in patients who have failed on prior lines of therapy. MVP-S is the clinical validation and proof of concept of the DPX platform’s potential in hematologic and solid cancer indications with and without CPIs.